Jindal Poly Film (JINDALPOLY)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Price-to-book of 0.52, trading at a large discount to book value of ₹1,366.67.
• Promoter holding of 74.55% aligns management interests with minority shareholders.
• Debt/equity of 0.84 is moderate, leaving some headroom in a capital-intensive business.
• Current price ₹709.90 is well below the 52-week high of ₹1,026.45, reducing some market optimism.
• Despite losses, the company pays a 0.96% dividend, showing some cash commitment to shareholders.

Concerns

• P/E is zero; latest quarter net loss was ₹97 Cr on ₹372 Cr sales, implying severe margin distress.
• Sales growth of -68.66% and profit growth of -453.42% show the business is shrinking sharply.
• ROE of 2.55% and ROCE of 5.36% are far below any reasonable cost of capital.
• Piotroski F-Score of 3/9 and FairStock Score of 0/100 flag high financial risk.

AI Analysis

When I look at Jindal Poly Film, the first thing I see is a price of ₹709.90 against a book value of ₹1,366.67 — a P/B of 0.52. Graham would call that a bargain if the book value is real and earnings will eventually appear. But my partner Charlie would say the P/E is zero for a reason: this business is currently earning nothing. Sales have collapsed by 68.66%, profits have turned down by 453.42%, and the latest quarter lost ₹97 crore on sales of ₹372 crore. That is roughly a 26% net loss on a quarter's revenue. At 74.55%, promoters have plenty of skin in the game; that aligns interests, but it does not replace profits. Debt-to-equity of 0.84 is manageable, yet the balance sheet needs to survive while the operating side heals. ROE of 2.55% and ROCE of 5.36% tell me the assets are not generating a satisfactory return; they may still have value, but they are not productive assets earning their keep. The dividend yield of 0.96% is a small comfort, and I would not rely on it. With a Piotroski F-Score of 3/9 and a FairStock Score of 0/100, every tool I use flags financial weakness. So what do I see? A cigar-butt asset play, not a wonderful franchise. At half book value, the downside is cushioned only if book value is protected. I need a catalyst: operational improvement, asset sale, or disciplined capital allocation. Without it, a low price can become a value trap. I will not buy just because it is cheap; I will wait for the numbers to show the patient is getting better.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer